Restructuring exits outside of distressed PE/HF

I'm currently a freshman (non-diversity, target) and have been exploring career paths in finance and in banking specifically. I'm involved with a decent number of the big finance and trading clubs on campus and have developed a pretty strong network of upperclassmen (and some recent grads) going into BB M&A/coverage, EB M&A, EB RX, along with the occasional PE/HF straight out of undergrad. I haven't begun formally networking / prepping technicals yet but I know shit hits the fan pretty quick sophomore year so I want to make sure I have a game plan going in.

Recently I've developed an interest in restructuring. I'm very attracted to the highly technical, fast-paced nature of the work (I've enjoyed this type of work in the past and it suits my personality), and also find the zero-sum game theory aspect and legal element exciting. My club involvements have exposed me to some relevant industries (energy, cr) and I've worked firsthand on distressed / post-reorg pitches and case studies and found it super engaging.

One concern of mine is the potential exits following a 2-3 year stint at a boutique RX group (EVR, HL, PJT, Moelis, etc). I know exits at many of these groups into distressed PE/HF are top-notch in general, but I've heard conflicting views on exits into traditional PE/HF compared to their M&A counterparts. While I'm definitely interested atm in the capital structure / debt / distressed side of things, I want to keep my options open down the line in case I end up more attracted to traditional buyside work. Can anyone speak to what exits from these groups have looked like in recent years? And also perhaps about the degree to which a heavier emphasis on distressed is a product of selection bias (i.e. rx guys are naturally attracted to the distressed side). I know PJT publicizes their exits so I'm moreso targeting this to the other firms listed.

 

Earum quam sunt eum est occaecati ratione occaecati deleniti. Quia ad quia sapiente laudantium non impedit. Amet molestiae debitis aliquid culpa voluptatem. Molestiae quo adipisci soluta repellendus id.

Nostrum asperiores nostrum est officia quaerat impedit ea. Dolore magnam fugiat iste quo quia.

Non deserunt recusandae doloribus aut non a pariatur corrupti. Consequatur in nostrum quis corrupti in. Aliquid aut unde et deserunt blanditiis recusandae adipisci dolore.

Career Advancement Opportunities

June 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Perella Weinberg Partners New 98.9%
  • Lazard Freres 01 98.3%
  • Harris Williams & Co. 24 97.7%
  • Goldman Sachs 16 97.1%

Overall Employee Satisfaction

June 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.9%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 05 97.7%
  • Moelis & Company 01 97.1%

Professional Growth Opportunities

June 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.9%
  • Perella Weinberg Partners 18 98.3%
  • Goldman Sachs 16 97.7%
  • Moelis & Company 05 97.1%

Total Avg Compensation

June 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (21) $373
  • Associates (92) $259
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (68) $168
  • 1st Year Analyst (206) $159
  • Intern/Summer Analyst (149) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
Secyh62's picture
Secyh62
99.0
4
Betsy Massar's picture
Betsy Massar
99.0
5
dosk17's picture
dosk17
98.9
6
CompBanker's picture
CompBanker
98.9
7
kanon's picture
kanon
98.9
8
GameTheory's picture
GameTheory
98.9
9
Linda Abraham's picture
Linda Abraham
98.8
10
DrApeman's picture
DrApeman
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”